Arcangeli, G. [14] |
Phase III prospective |
168 pat. |
Arm I: 80Gy/2Gy/40 fractions, ArmII: 62Gy/3.1Gy/20 fractions, 4x/week. |
82.1Gy |
74.2Gy |
daily portal imaging |
70 months |
- |
Arm I: 16% ≥ II° GI, Arm II: 11% ≥ II° GI., at 3 years. |
- |
Arm I: 17% ≥ II° GI, Arm II: 14% ≥ II° GI, at 3 years. |
Hypofraction-RT is not inferior to conventional RT. |
Dearnaley, D. [15] |
Phase III prospective |
Arm I: 153 pat. 74Gy; Arm II 153 pat. 60Gy and 151 pat. 57Gy. |
Arm I: 74Gy/2Gy/37 fx; Arm II: 57-60Gy/3Gy/19-20 fx. |
Arm II: 73.8/77.6Gy |
Arm II: 68.4/72Gy |
no |
50.5 months |
- |
At 2 years, 3 pat. (2 · 2%) in 74Gy group, 3 (2 · 2%) in 60Gy group, and 0 in 57Gy group ≥ II° GU. |
- |
At 2 years, 6 pat. (4 · 3%) in Arm I ≥ II° RTOG, 5 pat. (3 · 6%) in 60Gy group, 2 (1 · 4%) in 57Gy group. |
- |
Pollack, A. [16] |
Phase III prospective |
307 (ASTRO Update 2011) |
Arm I: 76Gy/2Gy/28 fx; Arm II: 70.2Gy/2.7Gy/26 fx. |
Arm II: 84.7Gy |
Arm II: 80Gy. |
no |
5 years |
Arm I: 54% > II°; 2% > III°; Arm II: 40% > II°; 8% > III°. |
Arm I: 8.3%; Arm II: 18.3% at 5 years |
Arm I: 8% ≥ II°; Arm II: 18% ≥ II° |
4.5% ≥ II° GI. |
biochem. recurrence 21.5% vs. 21.9% at 5 years |
McDonald, A.M. [31] |
Retrospective |
57 PORT and 31 WPRT |
70Gy/2.5Gy/ 28 fractions |
80.3Gy |
77Gy |
CBCT daily |
41 months |
18/31(58%) in PORT, 28/57(49%) in WPRT ≥ II° |
4/57(7%)in WPRT, 0% in PORT ≥ III° GU |
7/31(23%) in PORT, 23/57 (40%) in WPRT ≥ II° GI |
0% in PORT, 10/57(18%) in WPRT ≥ II° GI |
- |
Adkinson, J.B. [29] |
Phase I prospective |
53 pat. |
70Gy/2.5Gy/28 fractions |
80.3Gy |
77Gy |
yes |
25.4 months |
20/53(38%) ≥ II° GU |
14/53(27%) ≥ II° GU |
17/53(32%) ≥ II° GI |
4/53(8%) ≥ II° GI |
biochem. control (nadir +2) 81.2 ± 6.6%. |
Jereczek-Fossa, B.A. [51] |
Prospective longitudinal follow-up |
337 pat. cT1-2, 40.9% low-risk; 43.3% intermed-risk; 14.2% high-risk. |
70.2Gy/2.7Gy/26 frations |
84.7Gy |
80Gy |
BAT 72%, stereo X-ray 16.4%, CBCT 11.9% pat. |
19 months |
35% ≥ II° GU, 6.2% ≥ III° GU. |
10.4% ≥ II° GU, 1.6% ≥ III° GU. |
11.3% ≥ II° GI, 1.2% ≥ III° GI. |
7.5% ≥ II° GI, 1.3% ≥ III° GI. |
- |
Kupelian, P. A. [18] |
Retrospective |
770 pat, 34% low-risk, 28% intermed.-risk, 38% high-risk D'Amico criterien. |
70Gy/2.5Gy/28 fractions, but mean target dose was 75.3Gy at 2.7Gy! |
80.3Gy with 1.4Gy α/β-ratio (83.8Gy with 3.5Gy α/β-ratio in publication) |
77Gy |
IGRT with BAT tranabdominal ultrasound |
45 months |
33% Pat. 0°, 48% I°, 18% II°, 1% III° RTOG |
90.5% pat. 0°, 4.3% I°, 5.1% II°, 0.1%(1 pat.) III° RTOG |
51% pat. 0°, 40% I°, 9% II° RTOG |
89.6% pat. 0°, 5.9% I°, 3.1% II°, 1.4% ≥ III° RTOG |
At 5 years 94%, 83%, 72% for low-/intermed./high-risk respectively (Nadir + 2 ng/ml) |
Quon, H. [33] |
Prospective phase I-II |
97 pat. High-risk |
67.5Gy/2.7Gy/25 fractions |
81.4Gy |
77Gy |
IGRT with gold marker |
39 months median |
8% pat. 0°, 50% I°, 39% II°, 4% III° CTCAE
|
82% pat. 0°, 9% I°, 5% II°, 3% III°, 1% IV°. |
4% pat. 0°, 59% I°, 37% II° |
54% pat. 0°, 40% I°, and 7% II° |
4 year bFFS 90.5%. |
Martin, J. [40] |
Prospective phase I-II |
92 pat., mainly intermed./low risk |
60Gy/3Gy/20 fractions |
77.6Gy |
72Gy |
IGRT with gold marker |
38 months median |
32% pat. 0°, 43% I°, 25% II° RTOG |
90% pat. 0°, 7% I°, 3% II° RTOG |
66% pat. 0°, 22% I°, 11% II°, 1% IV° RTOG |
93% pat. 0°, 2% I°, 4% II° RTOG |
3 year biochemical control 76%. |